1
40
1
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/j.pediatrneurol.2015.03.019" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/j.pediatrneurol.2015.03.019</a>
Pages
31–46
Issue
1
Volume
53
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Pilot Study of Intensive Chemotherapy With Peripheral Hematopoietic Cell Support for Children Less Than 3 Years of Age With Malignant Brain Tumors, the CCG-99703 Phase I/II Study. A Report From the Children's Oncology Group.
Publisher
An entity responsible for making the resource available
Pediatric neurology
Date
A point or period of time associated with an event in the lifecycle of the resource
2015
2015-07
Subject
The topic of the resource
*Hematopoietic Stem Cell Transplantation/adverse effects; Antineoplastic Agents/administration & dosage/adverse effects; Brain Neoplasms/*therapy; Carboplatin/administration & dosage/adverse effects; Child; Children's Oncology Group; Cisplatin/administration & dosage/adverse effects; Combined Modality Therapy/adverse effects/methods; Consolidation Chemotherapy; Cyclophosphamide/administration & dosage/adverse effects/therapeutic use; Etoposide/administration & dosage/adverse effects; Feasibility Studies; Female; high-dose chemotherapy; Humans; Induction Chemotherapy; Infant; infant brain tumor; Male; Pilot Projects; Preschool; stem-cell support; Thiotepa/administration & dosage/adverse effects; Treatment Outcome; Vincristine/adverse effects/therapeutic use
Creator
An entity primarily responsible for making the resource
Cohen Bruce H; Geyer J Russell; Miller Douglas C; Curran John G; Zhou Tianni; Holmes Emi; Ingles Sue Ann; Dunkel Ira J; Hilden Joanne; Packer Roger J; Pollack Ian F; Gajjar Amar; Finlay Jonathan L
Description
An account of the resource
BACKGROUND: The primary goals of the Children's Cancer Group 99703 study were to assess the feasibility and tolerability of-as well as the response rate to-a novel dose-intensive chemotherapy regimen. METHODS: Between March 1998 and October 2004, 92 eligible patients were enrolled. Following biopsy/resection, patients received three identical cycles of Induction chemotherapy (vincristine, cyclophosphamide, etoposide, and cisplatin) administered every 21-28 days. Patients without tumor progression then received three consolidation cycles of marrow-ablative chemotherapy (thiotepa and carboplatin) followed by autologous hematopoietic cell rescue. RESULTS: The maximum tolerated dose of thiotepa was 10 mg/kg/day x 2 days per cycle. The toxic mortality rate was zero during induction and 2.6% during consolidation. Centrally evaluated response rates to induction and consolidation in evaluable patients with residual tumor were 73.3% and 66.7%, respectively. Disease progression rates on induction and consolidation were 4%. Five-year event-free survival and overall survival were 43.9 +/- 5.2% and 63.6 +/- 5% respectively. Gross total resection versus less than gross total resection were the only significant outcome comparisons: 5-year maximum tolerated dose and overall survival of 54.4 +/- 7% versus 28.9 +/- 7% (P = 0.0065) and 75.9 +/- 8% versus 48.7 +/- 8% (P = 0.0034), respectively. The 5-year maximum tolerated dose for localized (M0) versus metastatic (M1+) medulloblastoma was 67.5 +/- 9.5% versus 30 +/- 14.5% (P = 0.007). The 5-year maximum tolerated dose and overall survival for desmoplastic medulloblastoma patients versus other medulloblastoma were 78.6 +/- 11% versus 50.5 +/- 12% (P = 0.038) and 85.7 +/- 9.4% versus 60.6 +/- 11.6% (P = 0.046), respectively. CONCLUSIONS: This phase I dose-escalation study of marrow-ablative thiotepa regimen determined a maximum tolerated dose that had acceptable toxicity. Overall survival data justify this strategy for current Children's Oncology Group studies.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/j.pediatrneurol.2015.03.019" target="_blank" rel="noreferrer noopener">10.1016/j.pediatrneurol.2015.03.019</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
*Hematopoietic Stem Cell Transplantation/adverse effects
2015
Antineoplastic Agents/administration & dosage/adverse effects
Brain Neoplasms/*therapy
Carboplatin/administration & dosage/adverse effects
Child
Children's Oncology Group
Cisplatin/administration & dosage/adverse effects
Cohen Bruce H
Combined Modality Therapy/adverse effects/methods
Consolidation Chemotherapy
Curran John G
Cyclophosphamide/administration & dosage/adverse effects/therapeutic use
Department of Family & Community Medicine
Dunkel Ira J
Etoposide/administration & dosage/adverse effects
Feasibility Studies
Female
Finlay Jonathan L
Gajjar Amar
Geyer J Russell
high-dose chemotherapy
Hilden Joanne
Holmes Emi
Humans
Induction Chemotherapy
Infant
infant brain tumor
Ingles Sue Ann
Male
Miller Douglas C
NEOMED College of Medicine
Packer Roger J
Pediatric neurology
Pilot Projects
Pollack Ian F
Preschool
stem-cell support
Thiotepa/administration & dosage/adverse effects
Treatment Outcome
Vincristine/adverse effects/therapeutic use
Zhou Tianni